Please ensure Javascript is enabled for purposes of website accessibility

Why Berkeley Lights Wilted on Wednesday

By Eric Volkman – Aug 11, 2021 at 5:01PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company fell just shy of analyst estimates in its latest reported quarter.

What happened

Investor sentiment was dimming notably on Berkeley Lights (BLI 4.54%) Wednesday, with the stock falling by over 9%. This followed the cell biology company's double whiff on Q2 earnings.

So what

Wednesday morning Berkeley Lights revealed that for the quarter, it booked revenue of $19.25 million, a near-doubling of the $10.57 million it made in Q2 2020. Yet net loss worsened across that period, deepening to $18.2 million ($0.27 per share) from the year-ago result of $12.4 million.

Technician in a laboratory using a microscope.

Image source: Getty Images.

Both headline numbers didn't quite meet analyst projections. On average, prognosticators following the stock were anticipating $19.64 million on the top line, with a per-share net loss of $0.24.

Berkeley Lights said its growth was driven by increased demand for its cell analysis and processing platform, which is a cutting-edge product for the healthcare industry. The company quoted its CEO Eric Hobbs as saying, "We continue to focus on business development partnerships with industry leaders like Thermo Fisher and Bayer, to develop disruptive workflows and services."

The hope is that these partnerships will "not only expand the market opportunities for our platform, but also help us to achieve our mission by accelerating cell and gene therapy products into the clinic," Hobbs added.

Now what

Berkeley Lights expects that this strategy will keep the revenue growth motor humming. The company reaffirmed its top-line guidance for full-year 2021 of $90 million to $100 million, which would represent growth of at least 40% over the 2020 tally. It did not proffer any profitability estimates.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Berkeley Lights, Inc. Stock Quote
Berkeley Lights, Inc.
BLI
$2.76 (4.54%) $0.12
Thermo Fisher Scientific Stock Quote
Thermo Fisher Scientific
TMO
$539.75 (-0.05%) $0.28

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
351%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.